Latest Acute Kidney Injury (AKI) News
Treatment linked to improved long-term survival, regardless of underlying kidney function.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
The addition of aliskiren to enalapril led to more adverse events in patients with chronic heart failure without an increase in benefit.
Study finds no significant difference in the rates of all-cause mortality, major cardiac events, and hospital admission with hyperkalemia or AKI.
10% of the population worldwide is impacted by some form of kidney damage.
The trial was stopped for futility after 615 patients completed the study.
Acute kidney injury increased the likelihood of advanced chronic kidney disease in elderly patients.
Statin users had 30% increased odds of acute kidney injury and 36% increased odds of chronic kidney disease compared with non-users.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Results of some urine and blood tests are unlikely to affect diagnosis or management of acute kidney injury.
Even mild AKI with rapid recovery is associated with increased risk of chronic kidney disease stage 3 or higher.
Even surgery patients with stage 1 AKI without true organ damage had a 43% increase in cardiovascular mortality risk within 10 years compared with patients with no kidney disease.
CKD progression from stage 3 to stage 4 also was associated with increased risks of acute kidney injury and hospitalization.
AKI, albuminuria, eGFR considered separately or together can predict adverse outcomes in diabetes.
Fewer than half of patients with TFD-linked AKI had renal function recovery after drug withdrawal.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)